Inclusion of ganglioside G(M1) liposome encapsulated hemoglobin does not extend circulation persistence at clinically relevant doses

B. Goins, F. S. Ligler, A. S. Rudolph

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This investigation has evaluated the substitution of ganglioside G(M1) for dimyristoyl phosphatidylglycerol (DMPG) in the preparation of liposome encapsulated hemoglobin (LEH), with the intention of increasing the circulation persistence of this potential oxygen carrier. Although equivalent yields of each formulation were produced by microfluidization, the hemoglobin encapsulation efficiency was greater for G(M1)-LEH than DMPG-LEH. Similar particle sizes, phospholipid content, methemoglobin levels, and oxygen-carrying capacity were observed for both formulations. Zeta potential measurements to monitor liposomal surface charge showed G(M1)-LEH to be more electropositive than DMPG-LEH. Using differential scanning calorimetry, similar enthalpy values and hemoglobin structural transition temperatures were determined for both LEH formulations. Circulation persistence of each LEH formulation was determined following a 0.25 ml (1 g phospholipid/Kg body weight) or 0.5 ml (2 g phospholipid/Kg body weight) injection in mice. During the first 18 hours, G(M1)-LEH was cleared at a faster rate than DMPG-LEH at both dosages studied. Then the remaining liposomes of each formulation were removed with identical circulation profiles until no liposomes were remaining in circulation at either 50 hours (0.25 ml) or 72 hours (0.5 ml) post-injection. These data reveal that the use of ganglioside G(M1) to solely increase the circulation persistence of LEH was of little benefit.

Original languageEnglish (US)
Pages (from-to)9-25
Number of pages17
JournalArtificial Cells, Blood Substitutes, and Immobilization Biotechnology
Volume22
Issue number1
StatePublished - Mar 1994
Externally publishedYes

Fingerprint

G(M1) Ganglioside
Liposomes
Hemoglobin
Hemoglobins
Phospholipids
Body Weight
Oxygen
Methemoglobin
Injections
Transition Temperature
Differential Scanning Calorimetry
Conservation of Natural Resources
Zeta potential
Surface charge
Encapsulation
Particle Size
Superconducting transition temperature
Differential scanning calorimetry
Enthalpy

ASJC Scopus subject areas

  • Biotechnology
  • Biomedical Engineering
  • Biomaterials
  • Hematology

Cite this

Inclusion of ganglioside G(M1) liposome encapsulated hemoglobin does not extend circulation persistence at clinically relevant doses. / Goins, B.; Ligler, F. S.; Rudolph, A. S.

In: Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, Vol. 22, No. 1, 03.1994, p. 9-25.

Research output: Contribution to journalArticle

@article{91be7e06f24042a5b9d532b725ad9280,
title = "Inclusion of ganglioside G(M1) liposome encapsulated hemoglobin does not extend circulation persistence at clinically relevant doses",
abstract = "This investigation has evaluated the substitution of ganglioside G(M1) for dimyristoyl phosphatidylglycerol (DMPG) in the preparation of liposome encapsulated hemoglobin (LEH), with the intention of increasing the circulation persistence of this potential oxygen carrier. Although equivalent yields of each formulation were produced by microfluidization, the hemoglobin encapsulation efficiency was greater for G(M1)-LEH than DMPG-LEH. Similar particle sizes, phospholipid content, methemoglobin levels, and oxygen-carrying capacity were observed for both formulations. Zeta potential measurements to monitor liposomal surface charge showed G(M1)-LEH to be more electropositive than DMPG-LEH. Using differential scanning calorimetry, similar enthalpy values and hemoglobin structural transition temperatures were determined for both LEH formulations. Circulation persistence of each LEH formulation was determined following a 0.25 ml (1 g phospholipid/Kg body weight) or 0.5 ml (2 g phospholipid/Kg body weight) injection in mice. During the first 18 hours, G(M1)-LEH was cleared at a faster rate than DMPG-LEH at both dosages studied. Then the remaining liposomes of each formulation were removed with identical circulation profiles until no liposomes were remaining in circulation at either 50 hours (0.25 ml) or 72 hours (0.5 ml) post-injection. These data reveal that the use of ganglioside G(M1) to solely increase the circulation persistence of LEH was of little benefit.",
author = "B. Goins and Ligler, {F. S.} and Rudolph, {A. S.}",
year = "1994",
month = "3",
language = "English (US)",
volume = "22",
pages = "9--25",
journal = "Artificial Cells, Nanomedicine and Biotechnology",
issn = "2169-1401",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Inclusion of ganglioside G(M1) liposome encapsulated hemoglobin does not extend circulation persistence at clinically relevant doses

AU - Goins, B.

AU - Ligler, F. S.

AU - Rudolph, A. S.

PY - 1994/3

Y1 - 1994/3

N2 - This investigation has evaluated the substitution of ganglioside G(M1) for dimyristoyl phosphatidylglycerol (DMPG) in the preparation of liposome encapsulated hemoglobin (LEH), with the intention of increasing the circulation persistence of this potential oxygen carrier. Although equivalent yields of each formulation were produced by microfluidization, the hemoglobin encapsulation efficiency was greater for G(M1)-LEH than DMPG-LEH. Similar particle sizes, phospholipid content, methemoglobin levels, and oxygen-carrying capacity were observed for both formulations. Zeta potential measurements to monitor liposomal surface charge showed G(M1)-LEH to be more electropositive than DMPG-LEH. Using differential scanning calorimetry, similar enthalpy values and hemoglobin structural transition temperatures were determined for both LEH formulations. Circulation persistence of each LEH formulation was determined following a 0.25 ml (1 g phospholipid/Kg body weight) or 0.5 ml (2 g phospholipid/Kg body weight) injection in mice. During the first 18 hours, G(M1)-LEH was cleared at a faster rate than DMPG-LEH at both dosages studied. Then the remaining liposomes of each formulation were removed with identical circulation profiles until no liposomes were remaining in circulation at either 50 hours (0.25 ml) or 72 hours (0.5 ml) post-injection. These data reveal that the use of ganglioside G(M1) to solely increase the circulation persistence of LEH was of little benefit.

AB - This investigation has evaluated the substitution of ganglioside G(M1) for dimyristoyl phosphatidylglycerol (DMPG) in the preparation of liposome encapsulated hemoglobin (LEH), with the intention of increasing the circulation persistence of this potential oxygen carrier. Although equivalent yields of each formulation were produced by microfluidization, the hemoglobin encapsulation efficiency was greater for G(M1)-LEH than DMPG-LEH. Similar particle sizes, phospholipid content, methemoglobin levels, and oxygen-carrying capacity were observed for both formulations. Zeta potential measurements to monitor liposomal surface charge showed G(M1)-LEH to be more electropositive than DMPG-LEH. Using differential scanning calorimetry, similar enthalpy values and hemoglobin structural transition temperatures were determined for both LEH formulations. Circulation persistence of each LEH formulation was determined following a 0.25 ml (1 g phospholipid/Kg body weight) or 0.5 ml (2 g phospholipid/Kg body weight) injection in mice. During the first 18 hours, G(M1)-LEH was cleared at a faster rate than DMPG-LEH at both dosages studied. Then the remaining liposomes of each formulation were removed with identical circulation profiles until no liposomes were remaining in circulation at either 50 hours (0.25 ml) or 72 hours (0.5 ml) post-injection. These data reveal that the use of ganglioside G(M1) to solely increase the circulation persistence of LEH was of little benefit.

UR - http://www.scopus.com/inward/record.url?scp=0028389174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028389174&partnerID=8YFLogxK

M3 - Article

C2 - 8055100

AN - SCOPUS:0028389174

VL - 22

SP - 9

EP - 25

JO - Artificial Cells, Nanomedicine and Biotechnology

JF - Artificial Cells, Nanomedicine and Biotechnology

SN - 2169-1401

IS - 1

ER -